JPWO2019006283A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019006283A5 JPWO2019006283A5 JP2020500206A JP2020500206A JPWO2019006283A5 JP WO2019006283 A5 JPWO2019006283 A5 JP WO2019006283A5 JP 2020500206 A JP2020500206 A JP 2020500206A JP 2020500206 A JP2020500206 A JP 2020500206A JP WO2019006283 A5 JPWO2019006283 A5 JP WO2019006283A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- free base
- cancer
- fluoroquinolin
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527855P | 2017-06-30 | 2017-06-30 | |
| US62/527,855 | 2017-06-30 | ||
| PCT/US2018/040262 WO2019006283A1 (en) | 2017-06-30 | 2018-06-29 | AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020526520A JP2020526520A (ja) | 2020-08-31 |
| JP2020526520A5 JP2020526520A5 (https=) | 2025-03-14 |
| JPWO2019006283A5 true JPWO2019006283A5 (https=) | 2025-03-14 |
| JP7690284B2 JP7690284B2 (ja) | 2025-06-10 |
Family
ID=64742242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500206A Active JP7690284B2 (ja) | 2017-06-30 | 2018-06-29 | Ｉｄｏ阻害剤の非晶質形態および結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11236049B2 (https=) |
| EP (1) | EP3644993B1 (https=) |
| JP (1) | JP7690284B2 (https=) |
| KR (1) | KR102630575B1 (https=) |
| CN (1) | CN111093651B (https=) |
| AU (1) | AU2018294314B2 (https=) |
| CA (1) | CA3066789A1 (https=) |
| EA (1) | EA202090119A1 (https=) |
| IL (1) | IL271601B2 (https=) |
| MX (2) | MX391848B (https=) |
| SG (1) | SG11201911937UA (https=) |
| WO (1) | WO2019006283A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3645008A4 (en) * | 2017-06-30 | 2020-12-09 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PRODUCTION |
| MX2020005014A (es) * | 2017-11-17 | 2020-08-27 | Ericsson Telefon Ab L M | Se?alizacion de desplazamiento de ta en nr. |
| CN110357813A (zh) * | 2018-04-09 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途 |
| WO2020000236A1 (zh) * | 2018-06-27 | 2020-01-02 | 深圳仁泰医药科技有限公司 | (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型 |
| JP7608444B2 (ja) * | 2019-09-11 | 2025-01-06 | ブリストル－マイヤーズ スクイブ カンパニー | インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤 |
| WO2021108288A1 (en) * | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| AR120935A1 (es) * | 2020-01-02 | 2022-03-30 | Hutchison Medipharma Ltd | Derivados de amida y usos de los mismos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| EP3645008A4 (en) | 2017-06-30 | 2020-12-09 | Bristol-Myers Squibb Company | SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PRODUCTION |
-
2018
- 2018-06-29 US US16/624,490 patent/US11236049B2/en active Active
- 2018-06-29 MX MX2019014885A patent/MX391848B/es unknown
- 2018-06-29 IL IL271601A patent/IL271601B2/en unknown
- 2018-06-29 CA CA3066789A patent/CA3066789A1/en active Pending
- 2018-06-29 WO PCT/US2018/040262 patent/WO2019006283A1/en not_active Ceased
- 2018-06-29 SG SG11201911937UA patent/SG11201911937UA/en unknown
- 2018-06-29 AU AU2018294314A patent/AU2018294314B2/en active Active
- 2018-06-29 JP JP2020500206A patent/JP7690284B2/ja active Active
- 2018-06-29 CN CN201880044036.6A patent/CN111093651B/zh active Active
- 2018-06-29 EP EP18823337.3A patent/EP3644993B1/en active Active
- 2018-06-29 KR KR1020207002491A patent/KR102630575B1/ko active Active
- 2018-06-29 EA EA202090119A patent/EA202090119A1/ru unknown
-
2019
- 2019-12-10 MX MX2021015656A patent/MX2021015656A/es unknown
-
2021
- 2021-12-16 US US17/553,434 patent/US12421195B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690284B2 (ja) | Ｉｄｏ阻害剤の非晶質形態および結晶形態 | |
| JP2022543155A (ja) | Ｈｐｋ１阻害剤の固体形態 | |
| JP2019528300A (ja) | インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法 | |
| JPWO2019006283A5 (https=) | ||
| WO2023122777A1 (en) | Oxime derivatives useful as t cell activators | |
| JP2021535182A (ja) | ホスホイノシチド３−キナーゼ（ｐｉ３ｋ）阻害剤の結晶形態 | |
| JP7829802B2 (ja) | 置換フェニルオキサゾロン化合物 | |
| AU2024314878A1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent | |
| WO2024254227A1 (en) | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound | |
| CN121368591A (zh) | 用于降低ikzf 1-4蛋白水平的经取代的噁唑酮化合物 | |
| US12527783B2 (en) | Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide | |
| EA041037B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| EA049146B1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| BR112019027259B1 (pt) | Formas amorfas e cristalinas de inibidores da ido, seus usos, e composição farmacêutica | |
| HK40127606A (zh) | 经取代的苯基恶唑酮化合物 |